精神分裂症血浆S100B蛋白测定及临床意义探讨

Investigation of clinical value of S100B plasma levels in patients with schizophrenia

目的探讨精神分裂症急性期血浆S100B蛋白水平及临床意义。方法用ELISA法检测血浆S100B蛋白含量。应用阳性和阴性症状量表(PANSS)评定精神症状。结果精神分裂症60例急性期血浆S100B蛋白水平(0.063±0.054μg/l)显著高于对照组(0.019±0.009μg/l,P<0.001);治疗6周后血浆S100B蛋白水平(0.079±0.093μg/L)与治疗前(0.063±0.054μg/L)差异不显著(P>0.05);治疗后血浆S100B持续增高者PANSS阴性症状评分较高。结论S100B持续增高与精神分裂症阴性症状相关。S100B绝对浓度可作为阴性症状发生的预测因子。

Objective To explore clinical value of S100B plasma levels in patients with schizophrenia of acute peroode. Methods S100B plasma levels were determined in 60 patients with schizophrenia and 60 matched healthy controls using Enzyme-Linked Immunosorbnent Assay（ELISA）. Positive and Negative Symptoms Scale （PANSS） was used to evaluate symptoms. Results Patients with schizophrenia showed significantly higher S100B levels （0. 063±0.054μg/l）than healthy controls（0. 019±0.009μg/l,P〈0. 001）. There was no significant difference of S100B between after 6-week treatment（0.063±0. 054μg/L）and before treatment （0. 079±0.093μg/L,P〉0.05）. Patients whose levels remained increased after treatment showed higher scores of negative symptoms in PANSS. Conclusion Continuously increasing S100B levels could be associated with negative symptoms of schizophrenia. The absolute S100B concentration maybe predicting factor for negative symptoms.